Business
Bioasis and Neuramedy Enter into Research Collaboration and License Agreement
Bioasis and Neuramedy Enter into Research Collaboration and License Agreement.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n NEW HAVEN, CONN., U.S.A., May 10, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC.. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company or “Bioasis”) a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced today that it has entered into a research collaboration and license agreement with Neuramedy Co Ltd (“Neuramedy”) of Seoul, Korea. Neuramedy is a biotech company researching and developing innovative solutions for neurodegenerative diseases. The company aims to provide disease modifying treatments for Parkinson’s disease and other synuclein related diseases. Under the terms of the agreement, Neuramedy has obtained worldwide rights to research, develop and commercialize an xB3TM version of its antibody, Tomaralimab, directed at the Toll-like receptor 2. Tomaralimab is currently in development for the treatment of Parkinson’s disease and Multiple System Atrophy. Bioasis will receive an upfront payment and may receive an additional US$72 million in milestone payments and a royalty on net sales. “We are excited to have entered into this agreement with Bioasis. We expect the xB3TM platform will improve the efficacy and safety of our Tomaralimab. Through the collaboration with the companies like Bioasis, we hope to provide solutions that can improve the lives of patients with neurodegenerative disorders,” said Seung Jae Lee, Ph. D., Neuramedy’s CEO. “We are very pleased to have entered into this agreement and excited to be working with Neuramedy on this new target for Parkinson’s disease and Alzheimer’s disease. Forming innovative partnerships with companies such as Neuramedy is an important part of our strategy to see the broadest possible uptake of promising technology. Our xB3TM BBB drug delivery platform has the potential to significantly advance the treatment of neurogenerative diseases, solving a major unmet clinical need and improving the lives of patients, said Deborah Rathjen, Ph.D., Bioasis’ Executive Chair. On behalf of the Board of Directors of Bioasis Technologies Inc.Deborah Rathjen, Ph.D., Chair & Chief Executive Officer Follow on:FacebookInstagramLinkedInTwitter BTI-CRP About Bioasis Bioasis Technologies Inc. is a b...